rs3757385的多态性增加了IRF5表达和全身氧化代谢物,保护泌尿器膀癌患者免受复发
Ariane P Souza1, Isabely M Silva1, Beatriz G L Vacario1
1Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, 86057-970, Brazil.
Molecular biology reports
|June 28, 2025
概括
IRF5基因变体rs3757385 (G等位基因) 和高氧化代谢物 (NOx) 与尿路膀癌 (UBC) 的更好的结果有关,减少复发和瘤侵入性.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 泌尿器膀癌 (UBC) 是一个重要的全球健康问题.
- 调查预后因素对于管理UBC至关重要.
- 干扰素调节因子5 (IRF5) 在免疫反应和瘤发生中发挥作用.
研究的目的:
- 评估IRF5 rs3757385多态与UBC易感性和预后的关联.
- 评估IRF5表达,氧化代谢物 (NOx) 和UBC预后指标之间的关系.
- 探索基因变异,NOx水平和UBC患者的临床结果之间的潜在相互作用.
主要方法:
- 在295名UBC患者和295名对照患者中,IRF5 rs3757385变异的基因定型.
- 在瘤和正常膀组织中测量血氧化代谢物 (NOx) 和IRF5表达.
- 基因表达数据的生物信息学分析 (TCGA) 和预后因素的统计评估.
主要成果:
- IRF5 rs3757385多态性与UBC敏感性没有关联.
- rs3757385的G基因组与复发率的降低和肌肉侵入性瘤的减少有关,特别是在高血压患者中.
- 在G等位基载体,男性,吸烟者和酒精消费者中观察到更高的IRF5表达. 高氧化物水平与G等位基因结合,表明对复发的保护.
结论:
- 在IRF5中rs3757385 G等位基因和高血NOx水平被确定为UBC的有利预后因素.
- 这些发现表明IRF5和NOx在预测UBC结果方面可能发挥作用.
- 进一步的研究可能会阐明这种治疗策略的关联背后的机制.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...